All In Biotech

Drug Trial Radar · NCT01879722

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

77

Actual

Start

Jun 2013

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.

Conditions

  • Schizophrenia

Interventions

  • TAK-063Drug

    TAK-063 tablets

  • TAK-063 PlaceboDrug

    TAK-063 placebo-matching tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) After 7 Days of DosingTime frame: Day 1 to Day 14
  2. Percentage of Participants With Markedly Abnormal Safety Laboratory TestsTime frame: Day 1 to Day 8
  3. Percentage of Participants With Markedly Abnormal Vital Sign MeasurementsTime frame: Day 1 to Day 8
  4. Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) ParametersTime frame: Day 1 to Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.